NCT07682012Completed
LungVision AI-Augmented Fluoroscopic Navigation for Intraoperative Pulmonary Nodule Localization
Clinical Feasibility, Localization Accuracy, and Safety of the LungVision System for Intraoperative Localization of Small Pulmonary Nodules During Thoracoscopic Surgery: A Prospective Single-Center Pilot Study
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
This prospective single-center pilot study evaluates the clinical feasibility, localization accuracy, and safety of the LungVision system-an AI-augmented fluoroscopic navigation platform-for real-time intraoperative localization of small pulmonary nodules during video-assisted thoracoscopic surgery (VATS). All enrolled patients underwent dual localization: preoperative marking via CT-guided dye injection or virtual bronchoscopic navigation (Broncus Archimedes), followed by intraoperative localization using the LungVision system. The primary outcome was localization success rate, defined as the proportion of patients achieving fluoroscopic tool-in-lesion confirmation. Secondary outcomes included complete resection rate, navigation time, total operative time, and perioperative complication rate.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 14 (actual)
- First submitted
- 27 Jun 2026
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Tri-Service General Hospital (TSGH)
- Diseases
- Lung cancer
- NCT number
- NCT07682012
What you commit to
- Study type: Interventional
- Participants enrolled: 14
- From 1 Jan 2024 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Bleeding tendency or current use of anticoagulants
- Cognitive impairment precluding autonomous consent
Age
- Age \>65 years
Other
- Pregnancy
- Impaired consciousness or inability to communicate
Who the study is looking for
- Age 18-65 years
- Scheduled to undergo thoracoscopic resection for solitary, subsolid, or ground-glass pulmonary nodules requiring localization
- Lesion characteristics and CT imaging indicating need for preoperative localization, as determined by the attending surgeon
- Able and willing to complete the study protocol
- Able to provide written informed consent
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tri-Service General Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
Related publications
- Real-Time AI-Augmented Fluoroscopic Navigation for Intraoperative Pulmonary Nodule Localization: Prospective Observational Pilot Study.JMIR Form Res · 2026 · PMID 42714956
This page is information, not medical advice. Discuss any trial with your doctor.